SAFETY PROFILE OF BARICITINIB IN PATIENTS WITH ACTIVE RA: AN INTEGRATED ANALYSIS

被引：15
|
作者：
Smolen, J. [1 ]
Genovese, M. [2 ]
Takeuchi, T. [3 ]
Hyslop, D.
Macias, W. L. [4 ]
Rooney, T. P. [4 ]
Chen, L. [4 ]
Dickson, C. [4 ]
Riddle, J. [4 ]
Cardillo, T. [4 ]
Winthrop, K. [5 ]
机构：
[1] Med Univ Vienna, Vienna, Austria
[2] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA
[3] Keio Univ, Tokyo, Japan
[4] Eli Lilly & Co, Indianapolis, IN 46285 USA
[5] Oregon Hlth & Sci Univ, Portland, OR USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2016年 / 75卷
关键词：
D O I：
10.1136/annrheumdis-2016-eular.1612
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
THU0166
引用
收藏
页码：243 / 244
页数：2
相关论文
共 50 条
  • [41] Efficacy and Safety of Baricitinib in Chinese Rheumatoid Arthritis Patients and the Subgroup Analyses: Results from Study RA-BALANCE
    Yang, Yue
    Li, Xing-Fu
    Zhang, Xiao
    Bao, Chun-De
    Hu, Jian-Kang
    Xu, Jian-Hua
    Li, Xiang-Pei
    Xu, Jian
    He, Dong-Yi
    Li, Zhi-Jun
    Wang, Guo-Chun
    Wu, Han-Jun
    Ji, Fei
    Zhan, Lu-Jing
    Zerbini, Cristiano A. F.
    Li, Zhan-Guo
    RHEUMATOLOGY AND THERAPY, 2020, 7 (04) : 851 - 866
  • [42] Efficacy and Safety of Baricitinib in Chinese Rheumatoid Arthritis Patients and the Subgroup Analyses: Results from Study RA-BALANCE
    Yue Yang
    Xing-Fu Li
    Xiao Zhang
    Chun-De Bao
    Jian-Kang Hu
    Jian-Hua Xu
    Xiang-Pei Li
    Jian Xu
    Dong-Yi He
    Zhi-Jun Li
    Guo-Chun Wang
    Han-Jun Wu
    Fei Ji
    Lu-Jing Zhan
    Cristiano A. F. Zerbini
    Zhan-Guo Li
    Rheumatology and Therapy, 2020, 7 : 851 - 866
  • [43] Relative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in comparison to adalimumab in patients with active rheumatoid arthritis
    Lee, Young Ho
    Song, Gwan Gyu
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2020, 79 (08): : 785 - 796
  • [44] Integrated safety analysis of baricitinib in adults with severe alopecia areata from 2 randomized clinical trials
    King, Brett
    Mostaghimi, Arash
    Shimomura, Yutaka
    Zlotogorski, Abraham
    Holzwarth, Katrin
    Issa, Maher
    Dutronc, Yves
    Stanley, Sarah
    Wu, Wen-Shuo
    Sinclair, Rodney
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB176 - AB176
  • [45] Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials
    King, Brett
    Mostaghimi, Arash
    Shimomura, Yutaka
    Zlotogorski, Abraham
    Choi, Gwang-Seong
    Blume-Peytavi, Ulrike
    Passeron, Thierry
    Holzwarth, Katrin
    Dutronc, Yves
    McCollam, Jill
    Yang, Fan Emily
    Stanley, Sarah
    Wu, Wen-Shuo
    Sinclair, Rodney
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188 (02) : 218 - 227
  • [46] Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials
    King, B.
    Mostaghimi, A.
    Shimomura, Y.
    Zlotogorski, A.
    Holzwarth, K.
    Issa, M.
    Dutronc, Y.
    Stanley, S.
    Wu, W. -S.
    Sinclair, R.
    Fotiou, K.
    ALLERGOLOGIE, 2022, 45 (08) : 607 - 607
  • [47] Long-term safety of leflunomide (LEF) in patients with RA: 2-year integrated analysis.
    Scott, DI
    Cohen, SB
    Emery, P
    Breedveld, F
    Kalden, J
    Strand, V
    ARTHRITIS AND RHEUMATISM, 2001, 44 (09): : S172 - S172
  • [48] Comparison of the efficacy and safety of tofacitinib and baricitinib in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials
    Bae, S-C
    Lee, Y. H.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2019, 78 (06): : 559 - 567
  • [49] An Integrated Safety Profile Analysis of Belatacept in Kidney Transplant Recipients
    Grinyo, Josep
    Charpentier, Bernard
    Pestana, Jose Medina
    Vanrenterghem, Yves
    Vincenti, Flavio
    Reyes-Acevedo, Rafael
    Apanovitch, Anne Marie
    Gujrathi, Sheila
    Agarwal, Mamta
    Thomas, Dolca
    Larsen, Christian P.
    TRANSPLANTATION, 2010, 90 (12) : 1521 - 1527
  • [50] Efficacy and safety of baricitinib in patients with active rheumatoid arthritis and inadequate response to tumour necrosis factor inhibitors: the 24-week phase 3 RA-BEACON study
    Zamani, O.
    Combe, B.
    Tony, H-P
    Burson, J. S.
    Tahir, H.
    Ostergaard, M.
    Augendre-Ferrante, B.
    Beselin, A.
    Larsson, E.
    Casillas, M.
    Smolen, J.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2016, 45 : 21 - 22
12345